title: Functional Myeloid-Derived Suppressor Cell Subsets Recover Rapidly after Allogeneic Hematopoietic Stem/Progenitor Cell Transplantation.
abstract: Myeloid-derived suppressor cells (MDSCs) are regulatory cell populations that have the ability to suppress effector T cell responses and promote the development of regulatory T cells (Tregs). They are a heterogeneous population of immature myeloid progenitors that include monocytic and granulocytic subsets. We postulated that given the rapid expansion of myeloid cells post-transplant, these members of the innate immune system may be important contributors to the early immune environment post-transplant. To evaluate the kinetics of recovery and function of MDSCs after allogeneic hematopoietic stem cell transplant (HSCT), 26 patients undergoing allogeneic HSCT were studied at 6 time points in the first 3 months after HSCT. Both MDSC subsets recovered between 2 and 4 weeks, well before the recovery of T and B lymphocytes. MDSC subset recovery positively correlated with T, B, and/or double-negative T cell numbers after HSCT. MDSCs isolated from patients post-transplant were functional in that they suppressed third-party CD4(+) T cell proliferation and Th1 differentiation and promoted Treg development. In conclusion, functional MDSC are present early after HSCT and likely contribute to the regulatory cell population post-transplant.
authors.affiliation: Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada; Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Qingdong
authors.initials: Q
authors.lastname: Guan
authors.affiliation: Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Anna R
authors.initials: AR
authors.lastname: Blankstein
authors.affiliation: Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Karla
authors.initials: K
authors.lastname: Anjos
authors.affiliation: Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Oleksandra
authors.initials: O
authors.lastname: Synova
authors.affiliation: Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Marie
authors.initials: M
authors.lastname: Tulloch
authors.affiliation: Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Angeline
authors.initials: A
authors.lastname: Giftakis
authors.affiliation: Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Bin
authors.initials: B
authors.lastname: Yang
authors.affiliation: Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Pascal
authors.initials: P
authors.lastname: Lambert
authors.affiliation: Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Zhikang
authors.initials: Z
authors.lastname: Peng
authors.affiliation: Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada; Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Geoff D E
authors.initials: GD
authors.lastname: Cuvelier
authors.affiliation: Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada; Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, Winnipeg, Manitoba, Canada. Electronic address: donna.wall@cancercare.mb.ca.
authors.forename: Donna A
authors.initials: DA
authors.lastname: Wall
mesh_terms: D000293:Adolescent; D000328:Adult; D001402:B-Lymphocytes / Q000276:immunology / Q000473:pathology; D002452:Cell Count; D002454:Cell Differentiation; D019070:Cell Lineage / Q000187:drug effects / Q000276:immunology*; D049109:Cell Proliferation; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology / Q000473:pathology; D006098:Granulocytes / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D019653:Myeloablative Agonists / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology; D013997:Time Factors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
chemical_list: D019653:Myeloablative Agonists
keywords: Allogeneic hematopoietic stem cell transplant; Graft-versus-host disease; Immune regulatory cells; Myeloid-derived suppressor cells; Recovery